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Supplementary Materials and Methods 
Plasmids, retroviruses, lentiviruses, and stable cell lines  
pOZ-N-Flag-HA-wtPHF8 and mutPHF8 (F279S) vectors were described previously (1). The 
sequences of the scrambled (control) shRNA and the shRNAs targeting the PHF8 ORF and 
3’UTR (1,2) were cloned into the AgeI and EcoRI sites of the Tet-pLKO-puro vector 
(doxycycline-inducible system) which was a gift from Dmitri Wiederschain (Addgene plasmid # 
21915) (3). These shRNAs were also cloned into the AgeI and EcoRI sites of the pLKO.1-TRC 
vector (constitutive expression system), which was a gift from David Root (Addgene plasmid # 
10878) (4). The MYC coding sequence (571-1890 bp) of NM_002467 was cloned into the XhoI 
and NotI sites of the pOZ-C vector to generate the pOZ-MYC construct. Cell lines stably 
expressing the pOZ constructs (MCF10A-Mock, -wtPHF8, -mutPHF8, double stable MCF10A 
cells expressing control or PHF8 shRNA-2 combined with empty vector (shCtrl_Mock or 
shPHF8-2_Mock), PHF8 shRNA resistant wtPHF8 (shPHF8-2_wtPHF8) or mutPHF8 (shPHF8-
2_mutPHF8); MCF10A-MYC; HaCaT-Mock and -MYC; MDA-MB-231-Mock and -PHF8; MT2-
Mock and -PHF8) were established as previously described (5). The conditionally regulated 
MYC (MYC-ER) construct was generated by fusing the MYC coding sequence in frame with the 
hormone-binding domain of the human estrogen receptor (ER), and was then subcloned into the 
pOZ-C vector. Briefly, the cells were infected with the corresponding retrovirus generated in 
Phoenix A cells, and were selected using dynalbead-conjugated anti-IL-2RA (Interleukin-2 
receptor alpha subunit) antibodies. MYC-ER expression was stimulated with 100 nM of 4-
hydroxy tamoxifen (4-OHT) (Sigma-Aldrich). Puromycin selection was used to establish Tet-On 
inducible cell lines stably expressing lentiviral vectors (MCF10A-control shRNA, -PHF8 ORF 
shRNA). Additional lines stably expressing non-inducible constructs were established in pLKO-
TRC vector in similar fashion (MT-2-control shRNA, and PHF8 ORF shRNA).  
 
RNA-seq and bioinformatics analysis 
Total RNA was isolated from MCF10A/control and MCF10A/PHF8 cells using the RNeasy Plus 
Mini Kit (Qiagen) following the manufacturer’s protocol. The efficiency of PHF8 overexpression 
was determined by immunoblotting and qRT-PCR. RNA-seq libraries were made using the 
TruSeq Stranded Total RNA LT Sample Prep Kit (with Ribo-Zero™ Human/Mouse/Rat, RS-122-
2201) and multiplexed with Illumina barcodes. Two biological duplicates of MCF10A/control and 
MCF10A/PHF8 samples treated with TGF-β1 for 0, 24, 48 and 72 hours were submitted for 
sequencing on a HiSeq2500 instrument following protocols supplied by Illumina (San Diego, 
CA). 50-bp paired-end reads were generated. More than 20 Mb reads were produced for each 
library. The paired-end raw reads were aligned against the hg19 assembly of the human 
genome using the TopHat (v2.0.13) program (6). Counts were generated using featureCounts 
from the Subread package (Release 1.4.6) (7), and the initial differential expression was 
assessed with DESeq2 (8). The heat map was generated by GENE-E software hosted at the 
Broad Institute (http://www.broadinstitute.org/cancer/software/GENE-E/). 
 
Gene set enrichment analysis  
Gene set enrichment (GSEA) was performed using the GSEA software (9,10). Dataset files 
were developed based on normalization of expression intensities by DESeq2. Specifically, the 
log2 fold change values were compared for two phenotypes in our analysis: MCF10A-Mock 
versus MCF10A-PHF8. GSEA was executed using the default settings, the permutation type 
was set to Gene_set with 1000 permutations, and the metric for ranking genes was set to 
Diff_of_Classes because normalized expression data by DESeq2 was log2 transformed. Three 
datasets of EMT signature genes were used as references. (11-13) Each EMT signature 
collection was analyzed individually in multiple GSEA runs. 
 
Transient transfection 
Cells were 80-90% confluent in 6-well plates when transfection experiments were conducted. 
miR-22 mimics (GenePharma) or inhibitors (Integrated DNA Technologies) were used at a final 
concentration of 90 nM or 3 nM, respectively. In the siRNA knockdown experiments, siRNA 
duplexes targeting the human PHF8 (OriGene, SR308029A and B) and MYC (OriGene, 
SR303025A and C) were used at a final concentration of 40 nM. After transfection for 48 hours 
(miRNA mimics and inhibitors) or 72 hours (siRNAs), cells were harvested for analysis of gene 
expression. All transfection of RNA duplexes was performed using the Lipofectamine RNAiMAX 
transfection reagent (Life technologies).  
 
Colony formation assays 
Both monolayer colony formation and anchorage-independent growth in soft agar were tested. 
All assays were conducted in triplicate, and three independent experiments were performed.  
For the monolayer colony formation assay, 500 cells that either stably expressed PHF8 or had 
been subjected to doxycycline-inducible PHF8 knockdown were plated in 6-well plates in 
triplicate, and allowed to grow in the appropriate culture medium for two weeks. Fresh medium 
was supplied every 3 days. Colonies were stained with 0.1% crystal violet dye after being fixed 
in 4% paraformaldehyde.  Colonies larger than 5 μm in diameter were counted as positive for 
growth. 
To assay anchorage-independent growth in soft agar, MDA-MB-231 and BT474 cells subjected 
to doxycycline-inducible PHF8 knockdown by shRNAs were added to 1.5 ml of growth medium 
with 0.4% agar and layered onto 2 ml of 0.7% agar beds in six-well plates, respectively. Cells 
were fed with 1 ml of medium in 0.4% agar every 4 days for 3 weeks, after which the colonies 
were stained with 0.01% crystal violet overnight and photographed. The number of colonies 
larger than 100 µm in diameter was counted. 
 
Transwell migration assay 
MDA-MB-231 and MCF10A cells subjected to doxycycline-inducible PHF8 knockdown, or 
expressing pOZ-PHF8-HA or control plasmid, were serum-starved for 4 hours. A total of 3×104 
cells/well was added to the top chambers of 24-well transwell inserts (Corning Costar; 8-μm 
pore size). The lower compartment was filled with standard cell culture medium. Cells were 
allowed to migrate for 18-20 hours, after which 4% paraformaldehyde was added to each 
chamber for 10 minutes.  Membranes were stained with 0.1% (w/v) crystal violet for 20 minutes 
and subsequently washed thoroughly with PBS to visualize nuclei. Cells that had not migrated 
to the lower compartment were removed with a cotton swab. The number of migrating cells was 
counted using the ImageJ software. Experiments were repeated a minimum of three times. Data 
are shown as the mean ±S.D. of three independent experiments. 
 
Acinar formation assay 
Acinar formation of MCF10A cells in 3D Matrigel cultures was performed as described by 
Debnath et al. (14). Briefly, a total of  5×103 cells/well were plated in growth factor-reduced 
Matrigel (BD Biosciences, 354230) coated chamber slide (Falcon, 354108) and grown in 400 µl 
of DMEM:F12 medium supplemented with 2.5% Matrigel, 2% horse serum, 500 ng/ml 
Hydrocortisone, 10 µg/ml Insulin, 100 ng/ml Cholera Toxin and 5 ng/ml EGF. Media was 
changed every 4 days with assay media containing 2.5% Matrigel and 5 ng/ml EGF. Acini like 
structures were counted at day 12 and confocal image was taken using Carl Zeiss LSM 700. 
 
Cell proliferation assays 
Cell proliferation was assessed using the MTT assay, using at least three replicates. Cells were 
seeded in 96-well plates at 1×103 cells per well, and allowed to adhere overnight. Thereafter, on 
each day 20 µl of MTT (5 µg/µl in PBS) was added to the medium. Four hours later, the medium 
was removed with a needle and syringe, and blue formazan crystals trapped in the cells were 
dissolved in DMSO (120µl) by incubation at 37°C for 30 minutes. The absorbance at 490 nm 
was then measured using a Microplate Reader (VersaMax).  
 
Immunoblotting, immunofluorescence, immunohistochemistry and antibodies 
For immunoblotting experiments, cells were washed twice with cold PBS and lysed at 4°C in 
RIPA buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 0.1%SDS, 1mM EDTA, 1% (vol/vol) 
Triton X-100, 1% sodium deoxycholate, 0.5mM EDTA, 1 mM sodium vanadate, 50 mM NaF and 
complete protease inhibitors (Roche). Lysates were cleared by centrifugation at 13000 rpm for 
10 minutes, and aliquots of the cell extracts containing equal amounts of protein were analyzed 
for protein expression by western blotting. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose filters (BioRad). Membranes were blocked in TBST buffer (10 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% (vol/vol) Tween-20) containing 5% (wt/vol) milk. 
Proteins were detected using the Amersham ECL reagent.  
 
For immunofluorescence experiments, cells were washed twice with PBS and fixed for 5 
minutes with 4% formaldehyde in PBS, then permeabilized for 5 minutes with 0.1% Triton X-
100. After rinses with PBS, blocking solution (2% BSA in PBS, pH7.5) was applied for 30 
minutes and primary antibodies were added in blocking buffer for 1 h at room temperature or 
overnight at 4°C. After two washes with PBS/0.1% Triton X-100 for 10 minutes, cells were 
incubated with DAPI, Alexa Fluor® 594 Phalloidin (A12381, Life Technologies) and secondary 
antibodies conjugated with fluorescent  dyes (Life Technologies) for 1 h, washed again with 
PBS/0.1% Triton X-100 for 10 minutes, and mounted in mounted in Vectashield mounting 
medium (Vector Laboratories). Slides were observed at 40× using a Nikon Eclipse 80i 
microscope, and images were recorded with a Nikon digital camera. 
 
For immunohistochemical staining, histological tissue arrays (BR10010c, BR1503d, BR244 and 
BR082a) purchased from USBIOMAX were routinely deparaffinized in xylene, 3 x 5 minutes, 
and rehydrated through an alcohol series. Protease-induced epitope retrieval was carried out 
and followed by heat-induced epitope retrieval. Tissues were pre-treated with trypsin working 
solution (0.05%) and incubated for 10–20 minutes at 37°C in a humidified chamber. Sections 
were allowed to cool down to room temperature. After a short rinse in distilled water, the 
sections were boiled in a microwave oven at 800 Watts in 100 ml of 0.01M citrate buffer (pH 
6.0) for 5 x 2 minutes. After treatment, the beaker was left on the bench to cool for 30 minutes. 
Endogenous peroxidase activity was blocked with 3% H2O2 in PBST for 10 minutes. After 
blocking in the blocking reagent (Immunoperoxidase Secondary Detection System, Millipore), 
immunohistochemical blotting was performed using PHF8 antibody (PHF8 IHC-00343, Bethyl 
Laboratories) and c-Myc Tag Antibody (MA1-980, ThermoFisher) at 1:100 dilution, in 
PBST with 1% goat serum. A sample lacking primary antibody served as the negative control. 
Biotinylated secondary goat anti-mouse IgG/goat anti-rabbit IgG (Millipore) antibody was used 
in labelling with IHC Select® Immunoperoxidase Secondary Detection System (Millipore) for 
PHF8 detection. The tissue arrays were examined using a Nikon Eclipse 80i microscope, and 
images were recorded using a Nikon digital camera. The expression levels of PHF8 and MYC 
were semi-quantitatively based on staining intensity and distribution using the immunoreactive 
score (IRS) as described by Su et al. (2014) (15). Primary antibodies were: anti-PHF8 for use in 
western blotting, made in house (1); anti-CDH1 (3195S), anti-CDH2 (13116S), anti-SNAI1 
(3879S), and anti-PTEN (9552S) purchased from Cell Signaling Technologies; anti-ZEB1 (sc-
25388), anti-c-MYC (sc-40), anti-β-actin (sc-47778), anti-HA (sc-7392), anti-VIM (sc-6260), anti-
p-SMAD2 (sc-135644), and anti-GFP (sc-9996) purchased from Santa Cruz Biotechnology; and 
anti-PHF8 for use in inmmunofluorescence, purchased from Abcam (ab36068). Secondary 
antibodies were anti-mouse- or anti-rabbit-conjugated horseradish peroxidase (BioRad). 
 
Real-time PCR assay 
RNA was isolated from 80% confluent plates of cells using TRIzol Reagent (Invitrogen). Total 
RNA (500 ng) was used for reverse transcription (RT) reactions using the M-MLV reverse 
transcriptase (Promega). Levels of expression for mature miRNAs and mRNAs were quantified 
by SYBR Green-based real-time PCR, using the iTaq Universal SYBR Green Supermix (Bio-
Rad). miRNA-specific primers were designed as described previously (16). Real-time PCR 
reactions for miRNA were performed as follows: one cycle of 95°C for 30 seconds followed by 
40 cycles of 95°C for 5 sections and 60°C for 20 sections. For mRNA detection, one cycle of 
95°C for 30 sections was followed by 40 cycles of 95°C for 10 sections, 55°C for 15 sections 
and 72°C for 25 sections. The expression levels of mRNAs and miRNAs relative to RPL13A or 
GAPDH and U6 snRNA, respectively, were determined using the 2-ΔΔCт method. Error bars 
represent standard deviations. Comparative real-time PCR was performed minimally in 
triplicate.  
 
Dual luciferase reporter assay 
Dual-luciferase reporters were derived from the psiCHECK-2 vector (Promega). The 3' 
untranslated region (UTR) of human PHF8 containing a wild type (wt) miR-22 binding site 
(PHF8-3'UTR-wt) or a mutated site complementary to the seed region of miR-22 (PHF8-3'UTR-
mut) was cloned into the downstream of the 3' UTR of the Renilla luciferase (hRluc) gene. HEK 
293T cells were plated in 48-well plates (4x104 per well) one day before transfection, and then 
were cotransfected with 100 ng of reporter plasmid (psiCHECK-3'UTR) and 20 nM of the 
synthetic miR-22 mimics or negative control (GenePharma). Transfection was performed using 
lipofectamine 2000 (Invitrogen), according to the manufacturer's protocol. Luciferase activities 
were measured 30 h post-transfection, using the Dual-Luciferase® Reporter Assay System 
(Promega) and an FB12 Luminometer (Berthold). For each sample, Renilla luciferase activity 
was normalized to firefly luciferase expression (Rluc/Fluc). Data shown are the Mean ± SD from 
at least three independent experiments performed in duplicate.  
 
Bioluminescent imaging 
For bioluminescent imaging, FVB/N mice were anesthetized and injected with 100 µl of D-
luciferin (15 mg/ml). Animals were imaged in an IVIS 200 chamber within 6 min after D-luciferin 
injection, and the photon flux were recorded using Living Image software (Xenogen) at the 
indicated time points. To measure tumor growth, photon flux was calculated for each mouse by 
using a circular region of interest over the tumor and normalized to the value obtained from the 






  Sequences Annotation 
PHF8 
   
PHF8_3'UTR Forward GCCTTCTCCACTGAGGAGCAGGTA 
qPCR targeting the 3'UTR of 
PHF8 
 Reverse CTCCTCATCCTGCCTTCCAGCTCT  
PHF8_ORF Forward GCAAACCGCAGCACCACACCT 
qPCR targeting the ORF of 
PHF8 





sequence targeting the 3’ UTR 
of PHF8 is underlined.  




sequence targeting the ORF of 





sequence targeting the ORF of 








siRNA for PHF8 








siRNA for MYC 
MYC Forward TTCGGGTAGTGGAAAACCAG   
  Reverse CCTCCTCGTCGCAGTAGAAA   
NCL Forward TGGCCCAGTCCAAGGTAACT   
  Reverse TGGCCCAGTCCAAGGTAACT   
CDK1 Forward GGCCAGAAGTGGAATCTTTACA   
  Reverse GGATCATAGATTAACATTTTC   
CDK4 Forward GAAACTCTGAAGCCGACCAG   
  Reverse AGGCAGAGATTCGCTTGTGT   
CDC25A Forward TAAGACCTGTATCTCGTGGCTG   
  Reverse CCCTGGTTCACTGCTATCTCT   
CCNA2 Forward CTGCATTTGGCTGTGAACTAC   
  Reverse ACAAACTCTGCTACTTCTGGG   
  Reverse TGAGCCATTCGCAGTTTCAC   
EMT-related genes and control 
TWIST1 Forward CCGGAGACCTAGATGTCATTG   
  Reverse CACGCCCTGTTTCTTTGAAT   
ZEB1 Forward CTGATTCTACACCGCCCAAA   
  Reverse AGCGCTTTCCACATTTGTCA   
ZEB2 Forward CGCAAACAAGCCAATCCCA  
 Reverse CACACTAGCTGGACTCGTCT  
CDH1 Forward CGAGAGCTACACGTTCACGG   
  Reverse GGGTGTCGAGGGAAAAATAGG   
CDH2 Forward CGACGAATGGATGAAAGACC   
  Reverse CATAGTCCTGCTCACCACCA   
SNAI1 Forward CCCTCAAGATGCACATCCGAA   
  Reverse TGGCACTGGTACTTCTTGACATCTGA   
GAPDH Forward ATGCCTCCTGCACCACCAAC  
 Reverse GGGGCCATCCACAGTCTTCT  
RPLP0 (36B4) Forward CCTGGAGGAGAAGAGGAAAGAGA  
 Reverse TTGAGGACCTCTGTGTATTTGTCAA  
CHGA Forward GGAGGATCGACCGACAGAC  
 Reverse GAGCAGAAGAGCCAGGACAG  
ChIP-qPCR 
   
SNAI1_1 Forward GGCCTAGCGAGTGGTTCTTC Targeting the TSS of SNAI1 
  Reverse CCAACGCACCTGGATTAGAG   
SNAI1_2 Forward CTCTGAGCGGTGAGGGTTAG 
Targeting the gene body of 
SNAI1  
  Reverse CCCAAAATAGAGCCCTGTGA   
ZEB1_1 Forward CGGCTTTACGACATCACCTT Targeting the TSS of ZEB1 
  Reverse CCACCACACCTGAGGAAAAC   
ZEB1_2 Forward TAGGGGAATGCGAGTGTTGT 
Targeting the gene body of 
ZEB1 
  Reverse CTCAAGGAGAAAACTACATCCCT   
GAPDH_1 Forward GCTCTCTGCTCCTCCTGTTC Targeting the TSS of GAPDH 
 Reverse CCTTCAGGCCGTCCCTAGC  
GAPDH_2 Forward GGCCTCCAAGGAGTAAGACC Targeting the 3’UTR of GAPDH 
 Reverse AGGGGTCTACATGGCAACTG  
CHGA_1 Forward GGAGGATCGACCGACAGAC Targeting the TSS of CHGA 
 Reverse GAGCAGAAGAGCCAGGACAG  
CHGA_2 Forward TTGAGGTTGTGCTCTTGTGG 
Targeting the gene body of 
CHGA 
 Reverse TGATCCCTGGTCCTGATTGT  
Luciferase assay 




The wild-type of miR-22 target 
site is underlined.  







The mutant of miR-22 target 
site is underlined 
























miR-182-5p_F Forward TGGCTTTGGCAATGGTAGAACT  
miRNA universal 
qPCR primer 
Reverse GTGCAGGGTCCGAGGT   
U6 Forward CGCTTCGGCAGCACATATAC Control for the miRNA assay 







Supplementary Figure Legends  
Supplementary Figure S1. PHF8 regulates acinar formation in MCF10A cells. (A) Western blot 
analysis of PHF8 expression in MCF10A-Mock and MCF10A-wtPHF8 cells (left panel), and cells 
expressing control shRNAs or PHF8 shRNAs (right panel). (B) The size of acini was measured 
on day 12. Immunostaining was performed for F-actin (red) and the apoptosis marker cleaved 
caspase-3 (green). Nuclei were co-stained with DAPI (blue). Scale bars, 50 μm. The dot plot 
shows the size distribution for each condition (right panel), with the median indicated by a 
horizontal line (at least 100 acini per experiment; **P < 0.001, Mann-Whitney test). 
 
Supplementary Figure S2. PHF8 regulates the cell morphology and expression of EMT-related 
genes induced by TGF-β1. (A) Western blot analysis of proteins encoded by selected EMT-
related genes in A549 cells stably overexpressing vector only (Mock), wild type PHF8 (WT), or 
mutant PHF8 (Mut). The relative signal intensities for indicated proteins are normalized to β-
actin and shown below each lane. (B) Western blot analysis of PHF8 expression in A549 cells 
with inducible expression of control shRNA or two different PHF8 shRNAs. (C) Morphological 
change induced by TGF-β1 at indicated time points in A549 cells expressing control or PHF8 
shRNAs. (D) qPCR analysis of RPLP0 in MCF10A-Mock and MCF10A-wtPHF8 cells treated 
with TGF-β1 treatment for 0 and 1.5 hours. (E) A heat map of the expression of Taube’s EMT 
genes (up and down regulated), retrieved from normalized RNA-seq data as in Figure 1F. (F) 
Normalized enrichment scores for the genes between MCF10A-Mock and MCF10A-wtPHF8 
cells treated with TGF-β1 for 24, 48 and 72 hours, using the EMT gene signatures of Taube et 
al. (2010) (13), Huang et al. (2012) (11) and Groger et al. (2012) (12), respectively. (G) qPCR 
analysis of GAPDH and CHGA expression in MCF10A cells expressing control shRNAs or 
PHF8 shRNA-2 without or with TGF-β1 treatment for 1.5 hours. (H) Western blot analysis of 
EMT-related genes in A549 cells expressing control or two different PHF8 shRNAs with TGF-β1 
treatment at different time points. (I and J) Comparison of cell morphology and proteins encoded 
by EMT-related genes in double stable MCF10A cells expressing control or PHF8 shRNA-2 
combined with empty vector (shCtrl_Mock or shPHF8-2_Mock), PHF8 shRNA-2 resistant 
wtPHF8 (shPHF8-2_wtPHF8) or mutPHF8 (shPHF8-2_mutPHF8). 
 
Supplementary Figure S3. ChIP-qPCR assay on TSS (amplicon 1) and gene body (amplicon 2) 
for GAPDH, ZEB1 and CHGA. (A) The amplicons of GAPDH, ZEB1 and CHGA for ChIP-qPCR 
were illustrated. (B) ChIP-qPCR assays with PHF8 antibody were performed for GAPDH, 
ZEB1 and CHGA. 
 Supplementary Figure S4. Western blot analysis of PHF8 expression in MCF10A and human 
breast cancer cell lines. The relative signal intensity for PHF8, normalized to β-actin, is shown 
below the lane. 
 
Supplementary Figure S5. PHF8 overexpression blocks TGF-β induced cell cycle arrest. 
Quantitation of the cycle distributions in MCF10A-Mock and MCF10A-wtPHF8 cells following 
treatment with TGF-β for the indicated time, as assessed by fluorescence activated cell sorting 
(FACS). P values represent three independent experiments. *: p<0.05, **: p<0.001; unpaired 
two-tailed Student’s t-test. 
 
Supplementary Figure S6. Schematic illustration of predicted sites of miRNA targeting within 
the PHF8 3’ UTR using TargetScan Human (Release 6.2). The seed sequences and 
complementary PHF8 sequences are shown.  
 
Supplementary Figure S7. PHF8 positively regulates anchorage-independent growth and 
tumor growth of breast cancer cells in vitro and in vivo.  (A) Western blot analysis of PHF8 
expression in MDA-MB-231, BT474 cells expressing control shRNA, siRNA or PHF8 shRNAs 
and siRNAs, respectively. (B) Soft agar colony assays in BT474 cells expressing doxycycline 
inducible control or PHF8 shRNAs. The quantification is shown at the right panel. (C) Western 
blot analysis of PHF8 expression in MDA-MB-231 overexpressing empty vector (Mock) or wild 
type PHF8. (D) Knockdown of PHF8 by shRNAs in MDA-MB-231 cells downregulated the 
expression of cell cycle and migration related genes, as detected by qPCR. SD was obtained 
from three independent experiments. *: p<0.05, **: p<0.01; unpaired two-tailed Student’s t-test. 
(E) Representative image of tumor growth of MDA-MB-231 cells stably expressing control and 
PHF8 shRNA implanted in nude mice. Tumors collected at week 6 after injections were weighed 
and assessed for volume, as quantitated at the right panel. **: p<0.01; unpaired two-tailed 
Student’s t-test. (F) Western blot analysis of PHF8 expression using anti-PHF8 antibody in MT2 
stable cell lines expressing control shRNAs or PHF8 shRNAs and SKBR3 cells. (G) IHC 
analysis of PHF8 expression in MT2 xenograft tumors. (H) MT2 stable cell lines expressing 
empty vector (Mock) or HA-tagged PHF8 was confirmed by western blotting using anti-HA 
antibody. (I) Representative image of tumor growth of mouse breast cancer MT2 cells in FVB/N 
mice into which MT2 cells stably overexpressing empty vector (Mock) or PHF8 were implanted. 
Tumors collected at day 60 were weighed and assessed for volume, as quantitated at the right 
panel. Error bars denote SD. *: p<0.05, **: p<0.01; Mann Whitney test (two-tailed) was used.   
 
Supplementary Figure S8. PHF8 is upregulated in breast cancers. (A) Levels of the PHF8 
mRNA in multiple cancer types based on RNA-seq data from The Cancer Genome Atlas 
(TCGA). (B) RNA-seq data from The Cancer Genome Atlas (TCGA) for PHF8 expression in 
breast cancers versus normal tissue was analyzed using StartBase 2.0. The case numbers are 
indicated in the parentheses. (C) Levels of the PHF8, JHDM1D and PHF2 mRNAs based on 
ONCOMINE analysis using the indicated thresholds. (D) PHF8 mRNA expression in breast 
cancer samples from ONCOMINE. (E) Correlation of PHF8 expression with ERBB2, ER and PR 
status, based on TCGA data for 593 cases of breast cancer. The number of cases is shown in 
parentheses.  
 
Supplementary Figure S9. PHF8 protein levels are positively correlated with metastasis in the 
MMTV-ERBB2 mouse model of breast cancer. IHC analysis of PHF8 expression in small and 
large tumors obtained from six and eight month old MMTV-ERBB2/FVB mice with anti-PHF8 
antibody (1). Nuclei were counterstained with Surgipath Hematoxylin. Tumor stages are 
indicated. Images are at 20X magnification unless otherwise indicated.  
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Seed sequence 1: 131-137




3‘   AGUAUGUCGAUCUAU-UGGUUUCU 




miR-22 seed sequence: 1840-1847
5' ...UCUUGAUCUUUCAAA-GGCAGCUA...
|||||  ||||||| 
3' UGUCAAGAAGUUGACCGUCGAA 
5' ...GUGGUCUCUGCCCCC-UCUUGCCA...
||||    ||||||| 
3' UCGAUACGGUCGUAGAACGGA 




miR-182 seed sequence: 530-537




* : This seed sequence is shared by all 8 let-7 isoforms and miR-4500, 4458, 98


























































































































































































































































































































BLCA: Bladder Urothelial Carcinoma
BRCA: Breast invasive carcinoma
ESCA: Esophageal carcinoma
LIHC: Liver hepatocellular carcinoma
LUSC: Lung squamous cell carcinoma
STAD: Stomach adenocarcinoma
UCEC: Uterine Corpus Endometrial Carcinoma
LUAD: Lung adenocarcinoma
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Analysis type by cancer
Cancer vs. Normal
PHF8 PHF2 JHDM1D
Data type: mRNA; Cutoff: 1.5 fold, p<0.05; 
Gene ranking: Top 10% 
D









































































































































































Breast cancer  





change p value Reference 
Intraductal Cribriform Breast 
Adenocarcinoma (3) 1% 2.1 1.14E-12 TCGA Breast
1 
Mixed Lobular and Ductal Breast 
Carcinoma (7) 2% 2.2 7.90E-6 TCGA Breast 
Male Breast Carcinoma (3) 3% 1.6 7.51E-7 TCGA Breast 
Mucinous Breast Carcinoma (4) 5% 1.6 0.002 TCGA Breast 
Invasive Lobular Breast 
Carcinoma (36) 7% 1.9 3.63E-9 TCGA Breast 
Invasive Ductal Breast 
Carcinoma (389) 11% 2.0 7.15-17 TCGA Breast 
Invasive Ductal and Lobular 
Carcinoma (3) 19% 3.5 0.028 TCGA Breast 
Invasive Breast Carcinoma 
Stroma (53) 2% 2.3 1.30E-19 Finak Breast 
2 
Invasive Lobular Breast 
Carcinoma (7) 10% 1.6 0.041 Radvanyi Breast 
3 
Invasive Breast Carcinoma (154) 21% 1.5 0.019 Gluck Breast 4 
 1 compared with 61 normal tissues; 2 compared with 6 normal tissues; 3 compared to 9 normal tissues;  







































Normal tissue Small tumor Small tumor Small tumor (4X) Small tumor
Normal tissue Large tumor Large tumor Large tumor (4X) Large tumor
Mammary gland Lung metastasis 
Early stage Late stage
Supplementary Figure S9
Table S1. Summary of biological duplicated RNA-seq information. 







% of raw 
clusters 
per lane 







First round        
MCF10A/Mock-NC CGATGT 1,477 29,545,742 69.7 11.6 97.3 37.7 
MCF10A/Mock-TGFβ1-24hr TGACCA 1,554 31,084,892 70.8 12.2 97.4 37.8 
MCF10A/Mock-TGFβ1-48hr ACAGTG 1,554 31,086,940 69.9 12.2 97.2 37.7 
MCF10A/Mock-TGFβ1-72hr TAGCTT 1,599 31,985,712 68.4 12.5 97.2 37.7 
MCF10A/PHF8-NC CCGTCC 1,206 24,126,904 62.7 9.4 97.2 37.7 
MCF10A/PHF8-TGFβ1-24hr GTCCGC 1,557 31,148,960 62.6 12.2 97.0 37.6 
MCF10A/PHF8-TGFβ1-48hr GTTTCG 1,799 35,989,074 64.3 14.1 97.3 37.8 
MCF10A/PHF8-TGFβ1-72hr ACTGAT 1,739 34,772,914 63.3 13.6 97.6 37.8 
Secondary round 
       
MCF10A/Mock-NC CGATGT 1,702 34,031,810 68.0 13.0 97.0 37.6 
MCF10A/Mock-TGFβ1-24hr TGACCA 1,544 30,883,576 68.6 11.8 97.6 37.8 
MCF10A/Mock-TGFβ1-48hr ACAGTG 1,578 31,568,542 70.9 12.1 97.8 37.9 
MCF10A/Mock-TGFβ1-72hr TAGCTT 1,872 37,436,972 70.4 14.3 97.6 37.8 
MCF10A/PHF8-NC CCGTCC 1,366 27,328,602 65.4 10.5 97.6 37.8 
MCF10A/PHF8-TGFβ1-24hr GTCCGC 1,613 32,268,858 67.0 12.3 97.5 37.8 
MCF10A/PHF8-TGFβ1-48hr GTTTCG 1,765 35,293,844 68.5 13.5 97.5 37.8 
MCF10A/PHF8-TGFβ1-72hr ACTGAT 1,381 27,616,924 68.0 10.6 97.9 37.9 
 
 
 
